Switching from natalizumab administration at the day hospital to administration at home. A 1 year prospective study of patient experience and quality of life in 30 consecutive patients with multiple sclerosis (TYSAD-35)

BACKGROUND: In the context of the COVID-19 pandemic, French health authorities allowed the home administration of natalizumab by a healthcare-at-home service. We evaluated the patients’ perception of care quality following the transition from day-hospital to home natalizumab administration. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Lamy, Simon, Veillard, David, Doyen, Hélène, Kerbrat, Anne, Michel, Laure, Chretien, Emilie, Ousmen, Ahmad, Edan, Gilles, Le Page, Emmanuelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049890/
https://www.ncbi.nlm.nih.gov/pubmed/37001411
http://dx.doi.org/10.1016/j.msard.2023.104657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049890/
https://www.ncbi.nlm.nih.gov/pubmed/37001411
http://dx.doi.org/10.1016/j.msard.2023.104657

Ejemplares similares